Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for...
Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
MADISON, WISCONSIN (June 15, 2010)
Figure 1. Viability (blue) and death (red) of iCell™ Cardiomyocytes (CDI) in response to Staurosporine application measured simultaneously with MultiTox-Glo Multiplex Cytotoxicity Assay (Promega).
Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.
Currently CDI has validated a panel of cell-based cytotoxicity assays from Promega that use CDI's human induced pluripotent stem (iPS) cell-derived iCell™ Cardiomyocytes. Data presented at the recent Society of Toxicology and the Society of Biomolecular Sciences conferences by CDI demonstrate that Promega's multiplexed biomarker assays for cytotoxicity and cell viability can be used to identify known toxic agents with similar sensitivity as reported in the published literature (see figure).
CDI and its pharmaceutical collaborators have begun validating such assays in order to incorporate them into their routine discovery programs. Chris Parker, CDI's chief commercial officer, noted, "Pharmaceutical customers recognize the importance of using human models to perform their studies - but up until recently, human cell models that exhibited true human biology in vitro were difficult to come by. We have several pharmaceutical customers who've validated in vitro cardiotoxicity assays using iCell Cardiomyocytes, which have correlated well with previous data from cardiotoxicity studies in animal-based models." Ultimately, the union of these two technologies from Promega and CDI is expected to provide more biologically predictive data and drive the development of safer and more effective drugs.
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com
About Cellular Dynamics International
Cellular Dynamics International, Inc. (CDI) is a leading developer and marketer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based private equity fund. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com
Director, Corporate Affairs
Phone: (608) 274-4330
Sr. Director, Marketing & Communications
Cellular Dynamics International
Phone: (608) 310-5142
These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.
For more information about a press release or about Promega in general, contact Promega Corporate Affairs at 1-608-274-4330 or via our contact page.